Literature DB >> 9236672

Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis.

M Takahashi1, M Suzuki, K Kushida, S Miyamoto, T Inoue.   

Abstract

Pentosidine is one of the advanced glycation end-products and is formed by glycosylation and oxidation. The aim of this study is to investigate the relationship between serum and urinary pentosidine levels and the activity of rheumatoid arthritis (RA). Using HPLC with column switching, we measured pentosidine in serum and urine from 77 patients with RA and 62 normal control subjects. The clinical features, blood biochemistry and activity of inflammation were examined in RA patients. Serum and urinary pentosidine in RA were significantly higher than in controls. Pentosidine significantly correlated with age, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor, joint score and Lansbury Index in RA. The levels of pentosidine were higher in patients with active RA than in those with inactive RA. Serum and urine levels of pentosidine correlated with the activity of RA, and serum and urinary pentosidine may be a significant and novel marker for evaluating the disease status and the activity of RA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9236672     DOI: 10.1093/rheumatology/36.6.637

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  22 in total

Review 1.  [Rheumatology update. Current knowledge of etiology, pathophysiology, diagnosis, and therapy of selected arthritic disorders. Part I: pathogenesis and differential diagnosis].

Authors:  G Hein; P Oelzner; H Sprott; B Manger
Journal:  Med Klin (Munich)       Date:  1999-09-15

2.  Colchicum autumnale from Het Cruydtboeck by Rembertus Dodonaeus.

Authors:  A Boonen; L van de Putte
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

3.  Identification of the advanced glycation end products N(epsilon)-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis.

Authors:  S Drinda; S Franke; C C Canet; P Petrow; R Bräuer; C Hüttich; G Stein; G Hein
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 4.  Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Authors:  Morten A Karsdal; Mette J Nielsen; Jannie M Sand; Kim Henriksen; Federica Genovese; Anne-Christine Bay-Jensen; Victoria Smith; Joanne I Adamkewicz; Claus Christiansen; Diana J Leeming
Journal:  Assay Drug Dev Technol       Date:  2012-10-09       Impact factor: 1.738

5.  Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis.

Authors:  Yasunori Kageyama; Masaaki Takahashi; Eiji Torikai; Motohiro Suzuki; Tetsuya Ichikawa; Tetsuyuki Nagafusa; Yukio Koide; Akira Nagano
Journal:  Clin Rheumatol       Date:  2006-05-06       Impact factor: 2.980

6.  The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation.

Authors:  M M Anderson; J R Requena; J R Crowley; S R Thorpe; J W Heinecke
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

7.  Pentosidine in osteoarthritis: HPLC determination in body fluids and in tissues.

Authors:  Pavel Spacek; Milan Adam
Journal:  Rheumatol Int       Date:  2006-03-31       Impact factor: 2.631

8.  Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis.

Authors:  Richard Vytásek; Liliana Sedová; Vladimír Vilím
Journal:  BMC Musculoskelet Disord       Date:  2010-05-03       Impact factor: 2.362

9.  AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis.

Authors:  Per M Humpert; Ivan K Lukic; Suzanne R Thorpe; Stefan Hofer; Ezzat M Awad; Martin Andrassy; Elizabeth K Deemer; Michael Kasper; Erwin Schleicher; Markus Schwaninger; Markus A Weigand; Peter P Nawroth; Angelika Bierhaus
Journal:  J Leukoc Biol       Date:  2009-04-28       Impact factor: 4.962

10.  Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis.

Authors:  Yasunori Kageyama; Masaaki Takahashi; Tetsuyuki Nagafusa; Eiji Torikai; Akira Nagano
Journal:  Rheumatol Int       Date:  2007-07-28       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.